Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries ZyVersa Therapeutics, Inc. - Common Stock (NQ: ZVSA ) 3.370 +0.120 (+3.69%) Streaming Delayed Price Updated: 3:59 PM EDT, Aug 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about ZyVersa Therapeutics, Inc. - Common Stock < Previous 1 2 3 4 5 6 7 Next > 12 Health Care Stocks Moving In Monday's Pre-Market Session February 26, 2024 Via Benzinga Why Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today? February 26, 2024 ZyVersa Therapeutics stock is rising higher on Monday as shares of ZVDA experience heavy pre-market trading this morning. Via InvestorPlace Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday February 26, 2024 We're starting the trading week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday morning! Via InvestorPlace 12 Health Care Stocks Moving In Friday's After-Market Session February 23, 2024 Via Benzinga Why ZyVersa Therapeutics Shares Are Down 40% December 07, 2023 ZyVersa Therapeutics Inc (NASDAQ: ZVSA) shares are trading lower by 43.7% to $1.20 Thursday morning. Via Benzinga ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option February 22, 2024 From ZyVersa Therapeutics Via GlobeNewswire ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases February 14, 2024 From ZyVersa Therapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Friday's After-Market Session February 09, 2024 Via Benzinga ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones February 07, 2024 From ZyVersa Therapeutics Via GlobeNewswire ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes January 31, 2024 From ZyVersa Therapeutics Via GlobeNewswire ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease January 24, 2024 From ZyVersa Therapeutics Via GlobeNewswire Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session January 18, 2024 Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the... Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session January 18, 2024 Via Benzinga Why Is Inflammatory Disease-Focused ZyVersa Therapeutics Stock Trading Higher Today? January 17, 2024 ZyVersa reveals study in Acta Neuropathologica Communications. Learn how inhibiting NLRP3 inflammasome with Inflammasome ASC Inhibitor IC 100 prevents TNBC brain metastasis. Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session January 17, 2024 Via Benzinga ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis January 17, 2024 From ZyVersa Therapeutics Via GlobeNewswire ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access January 10, 2024 From ZyVersa Therapeutics Via GlobeNewswire ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets January 04, 2024 From ZyVersa Therapeutics Via GlobeNewswire ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024 January 03, 2024 From ZyVersa Therapeutics Via GlobeNewswire This Biotech Is Targeting Indications Worth $70 Billion December 22, 2023 Stephen C. Glover, Co-founder, Chairman, CEO and President of ZyVersa Therapeutics Inc. (NASDAQ: ZVSA) was recently a guest on Benzinga’s All-Access. Via Benzinga Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session December 19, 2023 Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy... Via Benzinga Why Motus GI Holdings Shares Are Trading Lower By Around 46%; Here Are 20 Stocks Moving Premarket December 19, 2023 Shares of Motus GI Holdings, Inc. (NASDAQ: MOTS) shares fell sharply in pre-market trading after the company priced its $5 million public offering. Motus GI Holdings shares dipped 46.5% to $1.15 in... Via Benzinga ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024” December 18, 2023 From ZyVersa Therapeutics Via GlobeNewswire ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200 December 14, 2023 From ZyVersa Therapeutics Via GlobeNewswire Dow Surges 100 Points; Ciena Posts Upbeat Earnings December 07, 2023 U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Thursday. The Dow traded up 0.28% to 36,155 while the NASDAQ rose 1.41% to 14,346.47. The S&P... Via Benzinga Topics Stocks Exposures US Equities Why Methode Electronics Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session December 07, 2023 Shares of Methode Electronics, Inc (NYSE: MEI) fell sharply during Thursday’s session following weak quarterly earnings. Via Benzinga Gold Moves Lower; Dollar General Earnings Beat Estimates December 07, 2023 U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded up 0.06% to 36,077.32 while the NASDAQ rose 1.09% to 14,301.04.... Via Benzinga Topics Earnings Stocks Exposures Financial US Equities ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes December 07, 2023 From ZyVersa Therapeutics Via GlobeNewswire Nasdaq Jumps Over 100 Points; US Jobless Claims Edge Higher December 07, 2023 U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.04% to 36,068.53 while the... Via Benzinga Topics Stocks Exposures US Equities Rivian (RIVN) Stock Just Scored a New ‘Buy’ Rating December 07, 2023 Rivian stock is gaining on Thursday after Stifel weighed in on RIVN shares with a buy rating and set a price target of $25 per share. Via InvestorPlace < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.